U.S. markets closed

Catalent, Inc. (CTLT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
116.26+1.07 (+0.93%)
At close: 4:02PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close115.19
Open115.92
Bid116.18 x 1300
Ask117.18 x 800
Day's Range115.36 - 116.88
52 Week Range79.65 - 127.68
Volume550,890
Avg. Volume912,296
Market Cap19.804B
Beta (5Y Monthly)1.43
PE Ratio (TTM)39.37
EPS (TTM)2.95
Earnings DateAug 30, 2021 - Sep 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est135.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-17% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Quest Diagnostics (DGX) Q2 Earnings Beat, Base Testing Strong
    Zacks

    Quest Diagnostics (DGX) Q2 Earnings Beat, Base Testing Strong

    According to Quest Diagnostics (DGX), Q2 is the first quarter since 2019 in which it has registered organic base testing revenue growth.

  • Catalent Plans $100M Expansion Of Biologics Capabilities At Italian Vaccine Plant
    Benzinga

    Catalent Plans $100M Expansion Of Biologics Capabilities At Italian Vaccine Plant

    Catalent Inc (NYSE: CTLT) will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities. The plant is currently filling vials of COVID-19 vaccines for AstraZeneca plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ). The company plans to install two 2,000-liter single-use bioreactors at the Anagni plant and the infrastructure required for another six 2,000-liter single-use bioreactors. The initial expans

  • Reuters

    CORRECTED-Catalent plans $100 mln expansion at vaccine plant in Italy

    Catalent expects the expansion will allow it by April 2023 to be able to make the drug substance for complicated biologic drugs, including COVID-19 vaccines or therapies like monoclonal antibodies. "In Europe there is a shortage of capacity of bioreactors for biologic (drugs)," Mario Gargiulo, Catalent's Region President of Biologics in Europe said in an interview. The company plans to install two 2,000-liter single-use bioreactors at the Anagni plant, as well as the infrastructure required for another six 2,000-liter single-use bioreactors.